Rutgers Researchers Call for Balanced Approach to E-Cigarette Use

Jul.25.2022
Rutgers experts urge balanced approach to examining latest trends in adult e-cigarette use, citing potential benefits and health concerns.

Researchers from Rutgers University are urging for a balanced approach to reviewing the latest trends in adult electronic cigarette use.


Assistant Professor Julia Chen-Sankey and Lecturer Michelle T of the Department of Health Behavior, Society, and Policy at Rutgers School of Public Health, along with Lecturer Bover-Manderski of the Department of Biostatistics and Epidemiology at Rutgers, suggest that while there are clear health concerns associated with using e-cigarettes, particularly among those who have not previously used tobacco products, there are also potential benefits that should not be overlooked.


Researchers at Rutgers University have published an invited commentary in the Journal of the American Medical Association (JAMA) Network Open, reviewing new data on the trend of electronic cigarette use among American adults. The researchers, Chen-Sankey and Bover-Manderski, are also members of the Rutgers Tobacco Studies Center. They discuss the necessity of public health approaches to achieve a balance between risks and potential of electronic cigarettes in promoting smoking cessation among adults who currently use combustible cigarettes.


This study raises important questions about the use of electronic cigarettes by adults in the United States. What did the study find and what questions does it pose for public health policy?


Chen-Sankey's research paper explores the latest trends in electronic cigarette use among adults in the United States in 2017, 2018, and 2020. One of the key findings is that while the use of e-cigarettes among young adults aged 18 to 20 has decreased from 2018 to 2020, it has increased among other age groups. Additionally, there has been an increase in the frequency of daily e-cigarette use among current users.


Perhaps the most shocking revelation is that the usage of e-cigarettes among those who have never smoked combustible cigarettes has significantly increased. While e-cigarettes may have the potential to aid in smoking cessation, there has also been a decrease in the number of traditional smokers attempting to quit.


Bover-Manderski: How can these contradictory findings be applied to health policies? It is important to strike a balance between new teenage users and older smokers who want to quit.


Question: How do we strike this balance?


Chen-Sankey suggests that certain policy developments and strategies could ensure the public health benefits of using e-cigarettes. For instance, the recent authorization of e-cigarette products in the United States. The Food and Drug Administration (FDA) through its PMTA review could help establish public trust in authorized e-cigarette products.


Bover-Manderski stated that in order to increase the acceptance of traditional smokers using e-cigarettes as a means to quit smoking, public health education and mass media dissemination strategies should focus on promoting the evidence-based results of e-cigarettes harm reduction.


Question: Why do some traditional adult smokers refuse to use e-cigarettes as a method to quit smoking?


Chen-Sankey stated that in the past five years, the appeal of e-cigarette products for traditional smokers interested in quitting has decreased, but they have become more attractive to non-smokers. Several factors can help explain this frustrating pattern.


Firstly, policies aimed at reducing youth use of electronic cigarettes may also decrease interest and use among adult smokers attempting to quit. Additionally, media coverage may be shaping smokers' understanding of e-cigarettes as the amount of reporting on the risks for youth using e-cigarettes outweighs the potential benefits for adult combustible cigarette users.


Bover-Manderski suggests that public health organizations and healthcare professionals may need to shift their focus from the potential benefits of using combustible tobacco products among adults, to the risks associated with young people using e-cigarettes.


Question: One highlight of this study was a significant decrease in the proportion of young people aged 18 to 20 who use e-cigarettes. What explains this decrease?


Chen-Sankey suggests that this discrepancy may be related to the Tobacco Act, which limits the sale of tobacco and nicotine products, including e-cigarettes, to this age group starting in January 2020. Another potential explanation is the national restrictions implemented in February 2020 on certain flavored e-cigarettes, which may have significantly reduced their appeal among young people.


Bover-Manderski stated that it is important to acknowledge the impact of COVID-19-related lockdowns and social distancing requirements, which may restrict opportunities for this demographic to use e-cigarettes in social or group settings.


I'm sorry, but I do not have context or any text to translate to standard journalistic English. Please provide more information.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09